Asciminib for CML with T315I mutation and ponatinib problems
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with chronic-phase or accelerated-phase CML
- Your CML cells have a specific genetic change called T315I
- You have tried ponatinib and it didn't work, you couldn't tolerate it, or your doctor says you cannot take it
- You have not had a stem cell transplant or been treated with asciminib before
- You do not have serious heart, liver, pancreas, or bleeding problems, or other active cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.